Aa
Cyclosporin trials
Finally it seems like there is research to find a cure w/o that nasty interferon. Does anyone know about this and possibly have any information?
First Candidate from SCYNEXIS Novel Cyclophilin Inhibitor Platform, SCY-635, Establishes Proof of Concept in HCV-Infected Adults
Research Triangle Park, NC -- January 8, 2009 -- Drug discovery company, SCYNEXIS, Inc., today announced top-line results from a Phase 1b randomized, double-blind, placebo-controlled study of its lead oral antiviral drug candidate, SCY-635, in adult patients with chronic hepatitis C (HCV) infection. Treatment with SCY-635 was well tolerated and produced a clinically relevant reduction in plasma HCV RNA. Full results of the study will be presented in 2009. SCY-635, a cyclophilin inhibitor, represents a new class of drugs for the treatment of HCV infection and is the first candidate from a broad platform of proprietary cyclophilin inhibitors developed by SCYNEXIS.
"These data are very encouraging, demonstrating the therapeutic potential of SCY-635 in patients with HCV as well as validating our core discovery platform which is focused on developing cyclophilin inhibitors for multiple diseases, including serious viral diseases, central nervous system disorders and autoimmune diseases," commented Dr. Yves Ribeill, President and Chief Executive Officer of SCYNEXIS. "Based on these promising results, we are actively planning the clinical and regulatory path forward for the development of SCY-635 and will continue to advance additional novel candidates from the platform for other therapeutic indications."
About the Clinical Trial
The clinical study was conducted as a Phase 1b, randomized, double-blind, placebo-controlled, multi-dose study in adult volunteers with genotype 1 chronic hepatitis C infection. SCY-635 was given as an oral capsule for 15 consecutive days.
About SCY-635 and SCYNEXIS' Cyclophilin Inhibitor Platform
SCY-635 represents a new class of therapeutic agents for the treatment of HCV infection. SCY-635 is the first candidate in a novel class of non-immunosuppressive cyclophilin inhibitors owned by SCYNEXIS. Cyclophilins are a family of enzymatic proteins that assist in the folding and transport of other proteins synthesized within a cell. Cyclophilin inhibitors, such as Cyclosporine A, have been used for decades for the prophylaxis of organ rejection in transplant patients. Scientists at SCYNEXIS have synthesized derivatives of Cyclosporine A in which cyclophilin binding activity is separated from calcineurin binding activity (which mediates immunosuppression). A growing body of scientific evidence indicates that non-immunosuppressive analogs of Cyclosporine A may have applications in multiple therapeutic areas. Cyclophilins play a central role in the pathophysiology of chronic viral infection, neurodegenerative diseases and malignant transformation. Cyclophilin inhibition therefore represents an attractive target for drug discovery and development.
First Candidate from SCYNEXIS Novel Cyclophilin Inhibitor Platform, SCY-635, Establishes Proof of Concept in HCV-Infected Adults
Research Triangle Park, NC -- January 8, 2009 -- Drug discovery company, SCYNEXIS, Inc., today announced top-line results from a Phase 1b randomized, double-blind, placebo-controlled study of its lead oral antiviral drug candidate, SCY-635, in adult patients with chronic hepatitis C (HCV) infection. Treatment with SCY-635 was well tolerated and produced a clinically relevant reduction in plasma HCV RNA. Full results of the study will be presented in 2009. SCY-635, a cyclophilin inhibitor, represents a new class of drugs for the treatment of HCV infection and is the first candidate from a broad platform of proprietary cyclophilin inhibitors developed by SCYNEXIS.
"These data are very encouraging, demonstrating the therapeutic potential of SCY-635 in patients with HCV as well as validating our core discovery platform which is focused on developing cyclophilin inhibitors for multiple diseases, including serious viral diseases, central nervous system disorders and autoimmune diseases," commented Dr. Yves Ribeill, President and Chief Executive Officer of SCYNEXIS. "Based on these promising results, we are actively planning the clinical and regulatory path forward for the development of SCY-635 and will continue to advance additional novel candidates from the platform for other therapeutic indications."
About the Clinical Trial
The clinical study was conducted as a Phase 1b, randomized, double-blind, placebo-controlled, multi-dose study in adult volunteers with genotype 1 chronic hepatitis C infection. SCY-635 was given as an oral capsule for 15 consecutive days.
About SCY-635 and SCYNEXIS' Cyclophilin Inhibitor Platform
SCY-635 represents a new class of therapeutic agents for the treatment of HCV infection. SCY-635 is the first candidate in a novel class of non-immunosuppressive cyclophilin inhibitors owned by SCYNEXIS. Cyclophilins are a family of enzymatic proteins that assist in the folding and transport of other proteins synthesized within a cell. Cyclophilin inhibitors, such as Cyclosporine A, have been used for decades for the prophylaxis of organ rejection in transplant patients. Scientists at SCYNEXIS have synthesized derivatives of Cyclosporine A in which cyclophilin binding activity is separated from calcineurin binding activity (which mediates immunosuppression). A growing body of scientific evidence indicates that non-immunosuppressive analogs of Cyclosporine A may have applications in multiple therapeutic areas. Cyclophilins play a central role in the pathophysiology of chronic viral infection, neurodegenerative diseases and malignant transformation. Cyclophilin inhibition therefore represents an attractive target for drug discovery and development.
Though I can't agree with all you've said, I do get frustrated at the amount of press HIV gets as opposed to the hidden quietness of HCV.
My husband thinks its because of the government not wanting to admit how many Vietnam Vets got it from the innoculations of the time.
They used these air guns and went from one bloody arm to another w/o cleaning them. Vietnam Vets are the most likely people to have HCV and it isn't from going to Nam. The government doesn't want to pay for all the people they've infected so HCV is kept as that 'dirty' disease that druggies get.
I wish Steve Jobs would come out and tell the truth but he's so damn secretive about everything. I'm 99% sure he has hep C.
My husband thinks its because of the government not wanting to admit how many Vietnam Vets got it from the innoculations of the time.
They used these air guns and went from one bloody arm to another w/o cleaning them. Vietnam Vets are the most likely people to have HCV and it isn't from going to Nam. The government doesn't want to pay for all the people they've infected so HCV is kept as that 'dirty' disease that druggies get.
I wish Steve Jobs would come out and tell the truth but he's so damn secretive about everything. I'm 99% sure he has hep C.
wow, great find and good hawk job there.
hey I remember about this stuff because when it first came out my neighbor was having a kidney transplant...and all the new research was proving it a MUCH better antirejection drug....but only UCLA and back east in Pittsburg were using it...I think it was called P37 or something like that...hard to remeber now...
sadly she would not believe me...since her "doctor" said no...but 2 kidneys later they finally put her on it. She passed this year and it saddened me, because all those years on much more toxic antirejection drugs took their toll. But there are many folk who will not listen to anything unless an MD follows ones name. Not my fault.
anyway, it makes some sense, look at Alinia, it's an antiparasitic and it help.
Stanford is looking again at all the old drugs with an HCV slant in mind.
Evidently they can screen hundreds now it the time it used to take for 10...so far they found one new/old antihistamine that also lowers VL in a dish.
My hope would be, even things that only lower VL would be in use and especially for those unable to treat, much as is done for HIV patients.
However, the concern seems to be "creating" a super strain in so doing.
Funny though, I don't remember this stopping them from treating HIV people with 100,000 a year worth of Rx's to keep them healthy. One more example of HCV people having no voice while others yell and get noticed. 7 times more people have HCV worldwide and yet the ratio is almost 3000 in HIV research for every 20 dollars spent on HCV research. How is it productive to spend 1-2% of the retrovirus research dollars on something killing 7 times more people?
One congressman even appropriated alloted HCV grants to HIV on his own.
The NIH sits by and nods at all this. When you see what our so called watchdog agencies are doing, FDA NIH or medicare already, it hardly makes me want to turn all our health care completely over to them.
It reminds me of when Chysler refused to spend an extra 2 bucks on a safer latch that kept people from flying out of their minivans...they decided it was cheaper to settle a few legal claims of dead people that to spend it on better latches...no government oversite, or if there is any it is misappropriated while the honchos sell their options and hedge their bets.
Did you catch the news blurp also on the new "health plan" about "some treatments may have to be foregone"...? That's code speak for HCV, transplant patients and ALL the like to expect to die for the good of the state, "spare us the expense and die already!".
Socialism at it's finest to be sure! Soylent Green here we come! Remember EGR's death scene?
Meanwhile if you sneak into the country you can expect our full health benefits.
But the folks who paid into the system their entire lives...well get in the back of the bus.
Meanwhile 70 million baby boomers will walk into a room full of IOU's in the next ten years. The heritage foundation has it at 78 million, but I'm being conservative because the drop in services will at least kill off some of us.
I should write a book..."How to bring down a country in 12 easy steps" although I think the kabals on both sides have already read it.
Wish I wasn't being so Orwellian here, but what's a girl to think!
mb
mb
hey I remember about this stuff because when it first came out my neighbor was having a kidney transplant...and all the new research was proving it a MUCH better antirejection drug....but only UCLA and back east in Pittsburg were using it...I think it was called P37 or something like that...hard to remeber now...
sadly she would not believe me...since her "doctor" said no...but 2 kidneys later they finally put her on it. She passed this year and it saddened me, because all those years on much more toxic antirejection drugs took their toll. But there are many folk who will not listen to anything unless an MD follows ones name. Not my fault.
anyway, it makes some sense, look at Alinia, it's an antiparasitic and it help.
Stanford is looking again at all the old drugs with an HCV slant in mind.
Evidently they can screen hundreds now it the time it used to take for 10...so far they found one new/old antihistamine that also lowers VL in a dish.
My hope would be, even things that only lower VL would be in use and especially for those unable to treat, much as is done for HIV patients.
However, the concern seems to be "creating" a super strain in so doing.
Funny though, I don't remember this stopping them from treating HIV people with 100,000 a year worth of Rx's to keep them healthy. One more example of HCV people having no voice while others yell and get noticed. 7 times more people have HCV worldwide and yet the ratio is almost 3000 in HIV research for every 20 dollars spent on HCV research. How is it productive to spend 1-2% of the retrovirus research dollars on something killing 7 times more people?
One congressman even appropriated alloted HCV grants to HIV on his own.
The NIH sits by and nods at all this. When you see what our so called watchdog agencies are doing, FDA NIH or medicare already, it hardly makes me want to turn all our health care completely over to them.
It reminds me of when Chysler refused to spend an extra 2 bucks on a safer latch that kept people from flying out of their minivans...they decided it was cheaper to settle a few legal claims of dead people that to spend it on better latches...no government oversite, or if there is any it is misappropriated while the honchos sell their options and hedge their bets.
Did you catch the news blurp also on the new "health plan" about "some treatments may have to be foregone"...? That's code speak for HCV, transplant patients and ALL the like to expect to die for the good of the state, "spare us the expense and die already!".
Socialism at it's finest to be sure! Soylent Green here we come! Remember EGR's death scene?
Meanwhile if you sneak into the country you can expect our full health benefits.
But the folks who paid into the system their entire lives...well get in the back of the bus.
Meanwhile 70 million baby boomers will walk into a room full of IOU's in the next ten years. The heritage foundation has it at 78 million, but I'm being conservative because the drop in services will at least kill off some of us.
I should write a book..."How to bring down a country in 12 easy steps" although I think the kabals on both sides have already read it.
Wish I wasn't being so Orwellian here, but what's a girl to think!
mb
mb
I dig up these reports sometimes while searching but if they aren't in simple laymen's terms, I can't decipher them.
Some of the trials with cyclosporin may be with interferon. I
had a tp and have been advised by a fellow transplantee to use cyclosporin as my immune suppresion med because of HCV. I'll run it by my doc when I see him in a couple of weeks and post here if he can enlighten us.
Some of the trials with cyclosporin may be with interferon. I
had a tp and have been advised by a fellow transplantee to use cyclosporin as my immune suppresion med because of HCV. I'll run it by my doc when I see him in a couple of weeks and post here if he can enlighten us.
I had a cyclosporine, called Debio-025, in combination with interferon in a 29-day trial in '07. Dramatic drop in viral load. I don't remember the stats, but the specialist said that it seemed likely, from the results, that I would respond significantly to Inf/Riba. Didn't work out that way though :(
Worse headaches with Debio/Inf than with Inf/Riba, but anyway, it would be interesting to try the cyclosporine alone. Apparently it's showing promise in muscular dystrophies also.
Worse headaches with Debio/Inf than with Inf/Riba, but anyway, it would be interesting to try the cyclosporine alone. Apparently it's showing promise in muscular dystrophies also.
Thank you for posting this. I had heard of a newer drug that didn't include SOC and was taken over around a 2 week period; but couldn't find any more. Perhaps this is it??
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
